CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.

Manufacturer of Condoms

November 14, 2026

To,
The Manager,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400051

SYMBOL: ANONDITA
ISIN: INE0VTV01012

Subject: **Statement of deviation or variation in the use of proceeds of Initial Public Offering under Regulation 32 of SEBI (LODR) Regulations, 2015**

Dear Sir/Madam,

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit that there has been no deviation/variation in the utilization of the proceeds from the Initial Public Offering as compared to the objects stated in the Prospectus as indicated in the Monitoring Agency Report submitted by Infomerics Valuation and Rating Limited dated November 14, 2026.

A Statement of Deviation or Variation for the half year ended September 30, 2026, duly reviewed by the Audit Committee and the Board of Directors at their meeting held on, i.e., November 14, 2026, is enclosed herewith as Annexure-A.

The above information is also being uploaded on the website of the Company.

Kindly take the above information on your records.

For and on behalf of
Anondita Medicare Limited

ANONDITA MEDICARE LIMITED

Anupam Ghosh
Managing Director
DIN: - 02675517
Address: - C-6, Near D M Residence, Sector-27,
Gautam Budhha Nagar, Uttar Pradesh-201301


UNIT


OFFICE


DIPPING AREA


TESTING AREA

Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.

Manufacturer of Condoms

Statement of Deviation / Variation in utilisation of funds raised

Name of listed entity	Anondita Medicare Limited
Mode of Fund Raising	IPO (Initial Public Offer)
Date of Raising Funds	28th August, 2025
Amount Raised	6949.85 Lakhs
Report filed for Quarter/ Half Year Ended	Half Year ended
Monitoring Agency	Yes
Monitoring Agency Name, if applicable	Infomerics Valuation and Rating Limited
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	NA
If Yes, Date of shareholder Approval	NA
Explanation for the Deviation / Variation	No deviation or variation has been reported by the Monitoring Agency in the utilisation of IPO proceeds.
Comments of the Audit Committee after review	The Audit Committee has reviewed the Monitoring Agency Report and noted that no deviation or variation has been reported in the utilisation of IPO proceeds.
Comments of the auditors, if any	Based on the records and documentation reviewed, the auditors have not observed any deviation or variation in the utilisation of IPO proceeds from the objects stated in the Prospectus.

ANONDITA MEDICARE LIMITED


UNIT


OFFICE


DIPPING AREA


TESTING AREA

Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

Objects for which funds have been raised and where there has been a deviation, in the following table						
Original Object	**Modified Object, if any**	**Original Allocation(in Lakhs)**	**Modified allocation, if any (in Lakhs)**	**Funds Utilised (in Lakhs)**	**Amount of Deviation/Variation for the quarter according to applicable object**	**Remarks if any**
Funding Working Capital Requirements	Due to revision in GCP limits (from 35% to 25%) under the revised SEBI guidelines, an amount of Allocation of Rs. 278.41 Lacs out of Object 3 (i.e., General Corporate Purposes) towards funding the Company's working capital requirements, including working capital loans and Cash Credit (CC) limits and with this reallocation, the revised total allocation for working capital now stands at Rs. 3,778.41 Lacs. Furthermore, utilization under this object has exceeded the originally estimated utilization during financial year 2025-26 and 2026-27 due to the Company's expanded scale of operations and higher working capital requirements and the working capital estimates were initially based on a projected turnover of ₹100 crore for FY 2025–26, which has now been revised to approximately ₹145 crore.	3500.00	3778.41	3778.41	NA	No deviation reported by the Monitoring Agency.
General Corporate Purpose (GCP)	Due to revision in GCP limits (from 35% to 25%) under the revised SEBI guidelines, the funds allocated for Object 3 (Unidentified Acquisition and General Corporate Purposes) will to be utilized for GCP only, now restricted to 25% of the total IPO proceeds. Any amount excess of	2015.87	1737.46	1737.46	NA	No deviation reported by the Monitoring Agency.

ANONDITA MEDICARE LIMITED


UNIT


OFFICE


DIPPING AREA


TESTING AREA

Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

	GCP Limit will be transferred towards meeting the Company's working capital requirements. No unidentified acquisition will be undertaken using the IPO proceeds. Furthermore, the allocation of Rs. 278.41 Lacs from Object 3 to Object 2 for funding the Company's working capital requirements, including working capital loans and Cash Credit Limit. With this reallocation, the revised total allocation for General Corporate Purposes stands at Rs. 1,737.46 Lacs. Further, while the utilization of these funds was initially projected over FY 2025–26 and FY 2026–27 and it was expected that the entire allocation was expected to be deployed within FY 2025–26 and yet the balance utilization will be made in this Financial year 2026-27.					
Capex	No variation in object of the issue except changes and/or additions to vendors, as disclosed in the Prospectus	600.00	NA	600.00	NA	No material deviation reported by the Monitoring Agency.
Issue expenses	NA	833.13	NA	833.13	NA	No deviation reported by the Monitoring Agency.

For and on behalf of
Anondita Medicare Limited

ANONDITA MEDICARE LIMITED

Anupam Ghosh
Managing Director
DIN: - 02675517
Address: - C-6, Near D M Residence, Sector-27, Gautam Budhha Nagar, Uttar Pradesh-201301


UNIT


OFFICE


DIPPING AREA


TESTING AREA

CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.
Manufacturer of Condoms

November 14, 2026

To,
The Manager,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400051

SYMBOL: ANONDITA
ISIN: INE0VTV01012

Subject: **Statement of deviation or variation in the use of proceeds of Right Issue under Regulation 32 of SEBI (LODR) Regulations, 2015**

Dear Sir/Madam,

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit that there has been no deviation/variation in the utilization of the proceeds from the Right Issue as compared to the objects stated in the Letter of Offer as indicated in the Monitoring Agency Report submitted by Infomerics Valuation and Rating Limited dated November 14, 2026.

A Statement of Deviation or Variation for the half year ended September 30, 2026, duly reviewed by the Audit Committee and the Board of Directors at their meeting held on, i.e., November 14, 2026, is enclosed herewith as Annexure-A.

The above information is also being uploaded on the website of the Company.

Kindly take the above information on your records.
For and on behalf of
Anondita Medicare Limited

ANONDITA MEDICARE LIMITED

Anupam Ghosh
Managing Director
DIN: - 02675517
Address: - C-6, Near D M Residence, Sector-27,
Gautam Budhha Nagar, Uttar Pradesh-201301



Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.

Manufacturer of Condoms

Statement of Deviation / Variation in utilisation of funds raised

Name of listed entity	Anondita Medicare Limited
Mode of Fund Raising	Right Issue
Date of Raising Funds	24th September, 2026
Amount Raised	₹9,102.58 Lakhs.
Report filed for Quarter/ Half Year Ended	Half Year ended
Monitoring Agency	Yes
Monitoring Agency Name, if applicable	Infomerics Valuation and Rating Limited
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	NA
If Yes, Date of shareholder Approval	NA
Explanation for the Deviation / Variation	No funds were utilised out of the proceeds raised through the Rights Issue up to September 30, 2026. Accordingly, no deviation or variation has arisen during the reporting period.
Comments of the Audit Committee after review	The Audit Committee has reviewed the statement and noted that no funds were utilised out of the Rights Issue proceeds up to September 30, 2026.
Comments of the auditors, if any	Based on the records and documentation reviewed, the auditors have observed that no funds were utilised out of the Rights Issue proceeds up to September 30, 2026. Accordingly, no deviation or variation in the utilisation of proceeds has arisen during the reporting period.

ANONDITA MEDICARE LIMITED


UNIT


OFFICE


DIPPING AREA


TESTING AREA

Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.

Manufacturer of Condoms

Objects for which funds have been raised and where there has been a deviation, in the following table

Original Object	Modified Object, if any	Original Allocation (in Lakhs)	Modified allocation, if any (in Lakhs)	Funds Utilised (in Lakhs)	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
Funding Working Capital Requirements	NA	2574.96	NA	NIL	NA	No deviation reported by the Monitoring Agency.
General Corporate Purpose (GCP)	NA	981.46	NA	NIL	NA	No deviation reported by the Monitoring Agency.
Capex	NA	5000.00	NA	NIL	NA	No material deviation reported by the Monitoring Agency.
Issue Related Expenses	NA	546.16	NA	NIL	NA	No deviation reported by the Monitoring Agency.

For and on behalf of
Anondita Medicare Limited

ANONDITA MEDICARE LIMITED

Anupam Ghosh
Managing Director
DIN: - 02675517
Address: - C-6, Near D M Residence, Sector-27,
Gautam Budhha Nagar, Uttar Pradesh-201301


UNIT


OFFICE


DIPPING AREA


TESTING AREA

Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.
Manufacturer of Condoms

November 14, 2026

To,
The Manager,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400051

SYMBOL: ANONDITA
ISIN: INE0VTV01012

Subject: **Statement of deviation or variation in the use of proceeds of Preferential Issue** of **Convertible warrants under Regulation 32 of SEBI (LODR) Regulations, 2015**

Dear Sir/Madam,

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit that there has been no deviation/variation in the utilization of the proceeds from the Preferential Issue of Convertible warrants to promoter category, as compared to the objects stated in the Notice of Extra Ordinary General Meeting along with the Explanatory Statement dated May 28, 2026.

A Statement of Deviation or Variation for the half year ended September 30, 2026, duly reviewed by the Audit Committee and the Board of Directors at their respective meeting held on, i.e., November 14, 2026, is enclosed herewith as Annexure-I.

Further, a certificate issued by the Statutory Auditors pursuant to NSE Circular No. NSE/CML/2024/23 dated September 05, 2024, in respect of the utilisation of funds raised through the Preferential Issue of Convertible Warrants into Equity Shares of Anondita Medicare Limited, is enclosed herewith as **Annexure II**.

The above information is also being uploaded on the website of the Company.

Kindly take the above information on your records.

For and on behalf of
Anondita Medicare Limited

ANONDITA MEDICARE LIMITED

Anupam Ghosh
Managing Director
DIN: - 02675517
Address: - C-6, Near D M Residence, Sector-27,
Gautam Budhha Nagar, Uttar Pradesh-201301


UNIT


OFFICE


DIPPING AREA


TESTING AREA

Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.

Manufacturer of Condoms


STATEMENT OF DEVIATION / VARIATION IN UTILIZATION OF FUNDS RAISED THROUGH PREFERENTIAL ISSUE- SHARE WARRANT

Name of listed Entity	Anondita Medicare Limited
Mode of Fund Raising	Preferential Issue of Convertible warrants to promoter category
Date of Issuance of Offer document	29-06-2026
Date of Raising Funds / Date of Allotment	08-07-2026
Total Amount of fund raised in the preferential issue	Rs 29,58,30,000 out of which Rs 7,39,57,500 (being 25% of the Warrant Issue Price) was received pursuant to allotment of Warrants dated 08-07-2026 and the balance 75% shall be receivable upon exercise of the Warrants.
Report filed for half year ended	30th September, 2026
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	No deviation or variation has arisen during the reporting period.
Comments of the Audit Committee after review	The Audit Committee has reviewed the statement and noted that no deviation or variation in the utilisation of proceeds has arisen during the reporting period.
Comments of the auditors, if any	Based on the records and documentation reviewed, the auditors have observed that no deviation or variation in the utilisation of proceeds has arisen during the reporting period.

ANONDITA MEDICARE LIMITED


UNIT


OFFICE


DIPPING AREA


TESTING AREA

Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

ANONDITA MEDICARE LIMITED

OBJECTS FOR WHICH FUNDS HAVE BEEN RAISED AND WHERE THERE HAS BEEN A DEVIATION, IN THE FOLLOWING TABLE:

Original Object	Modified Object, if any	Original Allocation (Rs. in lacs)	Modified allocation, if any (Rs. in lacs)	Fund Utilised (Rs. in lacs)	Unutilised (Rs. in lacs)	Amount of Deviation/Variation for the quarter according to applicable object (Rs. in lacs)	Remarks if any
Facility Establishment & Expansion, Product Development for International Markets, Digital Infrastructure, Technology Platforms, Brand Building, Marketing & Promotional Activities.	NA	*2958.30	NA	739.28	*2219.02	NA	NA

Note: **** Out of the total size of ₹2,958.30 Lakhs, ₹739.58 Lakhs (25%of Warrant Issue Price) has been received, out of which ₹739.28 Lakhs has been utilised and ₹0.29 Lakhs remains unutilised as on September 30, 2026. The balance 75%, amounting to ₹2,218.73 Lakhs, is receivable upon exercise of the Warrants. Accordingly, the total unutilised and receivable amount aggregates to ₹2,219.02 Lakhs.***

This is to certify that the above-mentioned information is true to the best of my knowledge and belief, according to the books and documents produced before me for verification.

Yours faithfully,
For and on behalf of
Anondita Medicare Limited

ANONDITA MEDICARE LIMITED

Anupam Ghosh
Managing Director
DIN: - 02675517
Address: - C-6, Near D M Residence, Sector-27,
Gautam Budhha Nagar, Uttar Pradesh-201301



Jain Chopra & Company

Chartered Accountants

8, Chandra House, First Floor, Dr. Lane, Gole Market, New Delhi - 110001
1960, First Floor, Outram Line, Delhi - 110009
Ph. : 011-42171194 Mob : 9810247478
E-mail : jainchopra.company@gmail.com

To,
The Board of Directors,
Anondita Medicare Limited
D-001, Sector-80, Gautam Budh Nagar,
Noida, Uttar Pradesh-201305

Sub: Certification under pursuant to NSE Circular No. NSE/CML/2024/23 dated September 05, 2024 for utilisation of funds in relation to Preferential Issue of Convertible Warrants into Equity Shares of Anondita Medicare Limited

1. We have examined the books of account, relevant records, bank statements and other supporting documents of **Anondita Medicare Limited** ("the Company") for the purpose of issuing this certificate in respect of utilisation of proceeds raised through the preferential issue of 2,85,000 (Two Lakh Eighty-Five Thousand) Convertible Warrants by the Company, to the Promoter Category.

2. Based on the information and explanations provided by the management, we understand that the Company has undertaken a preferential issue of 2,85,000 Convertible Warrants aggregating to Rs.29,58,30,000 (Rupees Twenty-Nine Crores Fifty-Eight Lakhs and Thirty Thousand Only).

3. Pursuant to the allotment of Warrants dated July 08, 2026, the Company has received Rs.7,39,57,500, representing 25% of the Warrant Issue Price. The balance 75% amounting to Rs.22,18,72,500 shall be receivable upon exercise of the Warrants, in accordance with the applicable terms and conditions.

4. Based on our examination and verification of the relevant books of account, records and supporting documents produced before us, and according to the information and explanations provided by the management, we hereby certify that, up to September 30, 2026, the Company has utilized Rs.7,39,28,019 out of the proceeds actually received towards the objects specified in the offer document.

5. The details of utilisation of funds, including the amount utilised and unutilised as at September 30, 2026, in accordance with NSE Circular No. NSE/CML/2024/23 dated September 05, 2024, are annexed herewith as **Annexure A**, forming an integral part of this certificate.

6. **Objects of the issue-**
The objects of the issue as stated in the Offer Document are as under
The objects of the issue as stated in the Offer Document are as under
"For establishment, expansion, Capital Expenditure for development of new products for international market; including construction, renovation, infrastructure development, equipment procurement, and all related expenditures, capital including pre-operative, gestation and until initial operational commissioning and stabilisation of such facility/facilities. Certification costs including UNFPA, CE etc. Digital

JAIN CHOPRA & COMPANY * NEW DELHI * CHARTERED ACCOUNTANTS

infrastructure, technology platforms, brand building, product development, and marketing and promotional activities across various channels."

No specific amounts have been indicated for individual activities under the aforesaid objects. Thus, no deviation in the utilization of proceeds from the stated objects of the issue has been observed.

7. Subject to above, we hereby certify that the above-mentioned information is true and correct to the best of our knowledge and belief, based on the books of account, records and documents produced before us for verification and the information and explanations provided by the management of the Company.

8. This certificate is issued pursuant to the aforesaid NSE Circular for submission to the National Stock Exchange of India Limited.

Yours faithfully,

For Jain Chopra & Company
Chartered Accountants
FRN: 002198N

Rajesh Kumar

Partner
M.No.: 501860
Place: Delhi
Dated: 14-11-2026
UDIN: 26501860NGFGRS3893



Jain Chopra & Company

Chartered Accountants

8, Chandra House, First Floor, Dr. Lane, Gole Market, New Delhi - 110001
1960, First Floor, Outram Line, Delhi - 110009
Ph. : 011-42171194 Mob : 9810247478
E-mail : jainchopra.company@gmail.com

Annexure A

Details of Utilization as on September 30, 2026

S.No	Object as disclosed in the Offer Document	Amount disclosed in the Offer Documents (in Lacs)	Actual Utilised Amount (in lacs)	Unutilised Amount (in lacs)	Remarks if any
1.	Facility Establishment & Expansion, Product Development for International Markets, Digital Infrastructure, Technology Platforms, Brand Building, Marketing & Promotional Activities.	*2958.30	739.28	2,219.02	NA

Note: Out of the total amount of Rs.2,958.30 Lakhs, an amount of Rs.739.58 Lakhs, representing 25% of the Warrant Issue Price, has been received. The balance amount of Rs.2,218.73 Lakhs, representing the remaining 75%, shall be receivable upon exercise of the Warrants, in accordance with the applicable terms and conditions.

We hereby certify that the above-mentioned information is true and correct to the best of our knowledge and belief, based on the books of account, records and documents produced before us for verification and the information and explanations provided by the management of the Company.

Yours faithfully,

For Jain Chopra & Company
Chartered Accountants
FRN: 002198N

Rajesh Kumar

Rajesh Kumar
Partner
M.No.-501860

JAIN CHOPRA & COMPANY * NEW DELHI * CHARTERED ACCOUNTANTS

Date: 14-11-2026
Place: New Delhi

UDIN: 26501860NGFGRS3893